Biosimilar Lispro

Biosimilar Lispro is a rapid-acting insulin analog being developed by Ice Bear Therapeutics for the treatment of Type 1 diabetes. As a biosimilar of insulin lispro, it is designed to mimic the pharmacokinetic and pharmacodynamic profile of the reference product, providing immediate glycemic control when administered before meals. The drug works by binding to the insulin receptor, which triggers cellular glucose uptake and inhibits hepatic glucose production, thereby lowering blood glucose levels. Ice Bear Therapeutics, a Social Purpose Company based in Seattle, focuses on utilizing innovative manufacturing technologies to ensure a more affordable and sustainable insulin supply. The product is currently in a pre-commercial development phase, with a forecasted commercial release in 2030.

Other names

LisproInsulin lispro biosimilar